Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03702244 · ClinicalTrials.gov registry record · NA
The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization
A NA study, sponsored by HeartFlow.
- Completed
- Registry status
- NA
- Development phase
- 2,103
- Enrollment target
NCT03702244: Completed NA study, sponsored by HeartFlow.
NCT03702244 is a NA study that has completed, run by HeartFlow. The registered enrollment target is 2,103 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03702244, a NA study, has completed, sponsored by HeartFlow.
- COMPLETED
- Registry status
- NA
- Development phase
- 2,103 participants
- Enrollment target
Study Summary
The study will be a prospective, pragmatic, randomized clinical trial of the comparative effectiveness of diagnostic evaluation strategies for stable CAD, to be performed in outpatient settings, including primary care and cardiology practices.
Primary Outcome
The centrally adjudicated (by Clinical Events Committee) primary end point was a composite of clinical efficiency as a gatekeeper to invasive testing (catheterization without obstructive CAD) and safety (death, non fatal myocardial infarction \[MI\]) at 1 year. Invasive cardiac catheterization without obstructive coronary artery disease defined as the absence of any ≥50% stenosis or hemodynamic indication of significance (no FFR ≤0.80 or iFR≤0.89) in any major epicardial vessel including side br
Interventions
- DIAGNOSTIC_TEST cCTA with selective FFRct
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,103 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2022-05-20 |
| Phase | NA |
What the finished NCT03702244 record still lists
NCT03702244 is an interventional study that assigns participants to a tested intervention. Its 2,103 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (50% higher).
The record links to 0 conditions, and to 1 intervention - of which cCTA with selective FFRct is the first listed.
NCT03702244 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03702244 about?
NCT03702244 is a clinical study titled "The PRECISE Protocol: Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization". The study will be a prospective, pragmatic, randomized clinical trial of the comparative effectiveness of diagnostic evaluation strategies for stable CAD, to be performed in outpatient settings, including primary care and cardiology practices.
What is the current status of trial NCT03702244?
This trial is currently completed. It is a NA study. The enrollment target is 2,103 participants. The study started on 2018-11-27. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT03702244?
The interventions under investigation include: cCTA with selective FFRct (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03702244?
This trial is sponsored by HeartFlow, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03702244's enrollment target sits among peer trials
2,103 49th of 2000 higher than 1,952 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05967273 · 2,106 participants · NA
CirrhosisRx CDS System
- NCT04649242 · 2,100 participants · Phase 3
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
- NCT05206331 · 2,100 participants · Phase 4
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
- NCT05270499 · 2,100 participants
Aveir VR Real-World Evidence Post-Approval Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI